Jake, I have a precise & published answer to give you. The

New Post Public Reply Private Reply Replies (3) Message Board
MGK_2 Jake2212 #163014
583
Jake, I have a precise & published answer to give you.
The short version: the early TNBC long-term survivors all received an ICI alongside or following leronlimab. That is not a coincidence. It is a prediction in the mechanism which the published biology now explains with specificity. Whether CLOVER patients can fare better without an ICI depends on which of leronlimab's four activity layers are doing the work in each individual patient's tumor, and the answer differs by patient.

The longer version follows.
The four patients in the early mTNBC cohort who are currently alive without evidence of disease after 42, 48, 49, and 52 months each had four prior lines of systemic therapy and were treated with leronlimab either in combination with, or subsequently with, checkpoint inhibitors: pembrolizumab or atezolizumab. 

This was published in ESMO Open in 2025 and it answers your question directly. The durable complete responses in the early TNBC cohort were not generated by leronlimab alone. They were generated by leronlimab in a setting where a checkpoint inhibitor was also present, either concurrently or sequentially. The patients who received leronlimab without an ICI did not achieve the same durable outcomes. The Dolezal, Khan, and Lalezari peer-reviewed case report documenting 60.9 months of sustained disease-free survival used atezolizumab as the ICI partner specifically. https://www.merck.com/news/fda-approves-merck...cer-whose/  

The explanation for why the ICI was required in those patients is now documented at single-cell resolution in the May 30, 2026 CCR5+ CD8+ T cell exhaustion paper. Leronlimab opens the upstream gate by blocking CCR5-mediated myeloid suppressive cell recruitment and reversing the exhaustion architecture imposed on tumor-infiltrating CD8+ T cells. But opening the gate does not independently activate the cytotoxic T cells waiting on the other side of it. The reinvigorated T cells still carry the PD-1 brake. Leronlimab upregulates PD-L1 expression on the tumor cell surface, as documented in the AACR IO February 2026 presentation, which is counterintuitive until you understand that PD-L1 upregulation is the tumor's way of signaling that the immune system is now pressing against it. Without an ICI releasing the PD-1 brake on those reinvigorated T cells, the gate is open but the T cells cannot execute the kill. The ICI is what converts the opened gate into a completed cytotoxic event.

This is exactly why the Dolezal, Khan, and Lalezari case report is so important: PD-L1 levels rose from 276 to 796 relative fluorescence units after leronlimab was added to atezolizumab. Leronlimab created the immunological conditions under which the ICI could function in a tumor previously classified as PD-L1 low and ICI-ineligible. The ICI then released the brake on the T cells that leronlimab had rescued from the exhaustion pipeline. The two mechanisms completed each other.

Now to your direct question about CLOVER: can CLOVER patients fare better without an ICI given that the backbone is TAS-102 plus bevacizumab rather than a checkpoint inhibitor?
The answer is: yes, for a distinct reason, and it is the fourth activity layer.
CLOVER patients are not receiving an ICI. They are receiving a DNA-damaging chemotherapy backbone in TAS-102, whose trifluridine component incorporates into tumor cell DNA and causes lethal strand breaks. As established in the previous reply, leronlimab's CCR5-dependent disruption of CEP131, KHDRBS1, and MAPK6 cell cycle regulators compromises the tumor cell's ability to repair those strand breaks and survive. The fourth activity layer is not dependent on having functional T cells present to complete a cytotoxic event. It operates directly at the tumor cell's metabolic and proliferative machinery. The Seahorse metabolic profiling from the AACR Brain Cancer poster confirmed this: CCR5 inhibition reduces oxygen consumption rate dose-dependently, meaning the tumor cell cannot fuel its repair response even when the immune architecture is not the primary therapeutic lever being pulled.

So the CLOVER patients occupy a different position than the early TNBC compassionate use patients. The early TNBC patients needed an ICI to complete the kill because leronlimab's primary therapeutic contribution in that setting was immune architecture conversion, opening a gate that required an activated T cell to walk through it and execute. 

The CLOVER patients have a DNA-damaging chemotherapy agent doing the killing work directly, and leronlimab's fourth activity layer is impairing the tumor cell's capacity to survive that damage at the metabolic and cell cycle level simultaneously. 

The immune architecture benefits of CCR5 blockade are still present and still valuable in CLOVER, but they are not the rate-limiting step for RECIST response the way they were in the early TNBC monotherapy context.

The historical ORR for TAS-102 plus bevacizumab alone in this population from the SUNLIGHT phase 3 trial was 6.3 percent. That is the benchmark the fourth activity layer needs to improve upon at RECIST. Whether it does so in sufficient numbers to constitute a meaningful ORR is what October at ESMO answers. https://www.sciencedirect.com/science/article...2822000877  

The early TNBC survivors needed leronlimab plus ICI because the mechanism required both gates to be addressed simultaneously. The CLOVER patients need leronlimab plus DNA-damaging chemotherapy because the mechanism in that combination addresses both the tumor's metabolic survival capacity and its immunological evasion architecture, without requiring a functional T cell kill to register a RECIST response. Different backbone, different rate-limiting step, same upstream gate providing the contribution.

Your friend asked the right question. The published biology answers it completely.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 92

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 94

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 52

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 28

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 71

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 89

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 81

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Trade Secret Damages Turn on Corporate Intent Evidence

Updated Category News Views 101

Suspicion may rattle a courtroom, but it apparently does not always loosen the jury’s purse strings. That is the useful, slightly sobering takeaway from DOAR’s new national study on damages in trade secret disputes, released November 20, 2026. Jurors, according to the report, draw a meaningful line between an employee carrying experience to a new job and a company...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 43

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 67

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading

Top 5 Most Recently Viewed Articles

PAPZIMEOS Emerges as the Go-To Treatment for RRP Patients

Updated Category News Views 104

PAPZIMEOS: A Promising New Standard for RRP Therapy PAPZIMEOS (zopapogene imadenovec) has gained recognition as an innovative treatment for adults suffering from recurrent respiratory papillomatosis (RRP). This breakthrough comes following the publication of a consensus paper authored by 16 leading experts in the field. Sponsored by the Recurrent Respiratory...

Continue Reading
Ollie's Bargain Outlet Reports Encouraging Q2 Results

Updated Category News Views 159

Ollie's Bargain Outlet Achieves Strong Q2 Performance Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) has made headlines recently as its shares experience fluctuations in the market. The company revealed impressive second-quarter adjusted earnings per share of 99 cents, surpassing analyst expectations of 94 cents. The quarterly sales reached $679.556 million, marking...

Continue Reading
Fivecast Introduces Groundbreaking Discovery Solution for OSINT

Updated Category News Views 184

Fivecast Unveils Discovery Solution to Combat Global Threats In today's rapidly evolving landscape of global threats, Fivecast, a prominent provider of advanced open-source intelligence (OSINT) solutions, has rolled out an innovative Discovery solution designed to assist analysts and investigators in both government and corporate settings. By elevating the speed and...

Continue Reading
Zen Technologies USA Advances Military Training with AI Simulations

Updated Category News Views 224

Zen Technologies USA Showcases Cutting-Edge AI Simulations Zen Technologies USA is set to revolutionize military training capabilities with its next-generation AI-enabled live and virtual simulation solutions. By enabling high-fidelity training for ground and naval forces, these innovations aim to accelerate the readiness of military units while significantly reducing...

Continue Reading
Sectra and Siemens Healthineers Transform Radiology Workflows

Updated Category News Views 494

Revolutionizing Radiology with Innovative Integrations International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG have formed a pivotal collaboration aimed at enhancing diagnostic capabilities in the radiology field. This initiative seeks to improve patient care by enabling seamless access to advanced imaging technologies....

Continue Reading